PROCESS FOR PRODUCTION OF INSULIN-LIKE GROWTH FACTOR I

Abstract: Processes for production of human insulin-like growth factor I (hereinafter referred to as IGF-I), IGF-I fused with a protective peptide, a gene coding for IGF-I, a gene coding for fused IGF-I, a plasmid containing IGF-I gene, a plasmid containing fused IGF-I gene, a host organism containing plasmid containing fused IGF-I gene, and processes for the production thereof. By this the human insulin-like growth factor I which is a protein hormone, can be synthesized in large quantities.

Description: This invention relates to processes for production of human insulin-like growth factor I (hereinafter referred to as IGF-I), to IGF-I fused to a protective peptide (hereinafter referred to as fused IGF-I), to a gene coding for fused IGF-I, to a plasmid containing fused IGF-I gene, to a host organism containing plasmid containing fused IGF-I gene, and to processes for the production thereof. Meanwhile, human insulin-like growth factor I is a protein hormone synthesized mainly in human tissues, liver and kidney which are stimulated by a certain hormone, and is found in human serum. IGF-I is known to have insulin-like potency and stimulation potency of sulfate-uptake by cartilage and may enhance protein and DNA synthesis in a cell. Therefore, it is useful in promoter of growth and may be useful in clinical treatment of diabetes. IGF-I is excreted in small amounts in human serum and may be isolated only few mg from human serum of several tons. Additionally, the producing cell of IGF-I was isolated in pure form, and it was found that IGF-I had biological properties as mentioned above, and its amino acid sequence has been reported in the literature. There exists, however, a need for a more viable commercial production of IGF-I, and such a requirement stimulate the accomplishment of this invention. It was perceived that the application of recombinant DNA and associated technologies would be the most effective way of producing large quantities of IGF-I. Therefore, the present invention is directed to a process for the production of IGF-I, which comprises subjecting IGF-I fused to a protection peptide to elimination reaction in which i) the protective peptide is a protein peptide having methionine as the last amino acid ii) the protective peptide is fused to IGF-I through said methionine, and iii) the elimination reaction is conducted with cyanogen bromide, to IGF-I fused to a protective peptide, wherein the protective peptide is a protein peptide having methionine as the last amino acid and is fused to IGF-I through said methionine, to a gene coding therefor, an expression vector containing such aforementioned gene and a promotor gene, a transformant containing such expression vector, and culturing process therefor. IGF-I is known to consist of 70 amino acids in the following sequence: The inventors of this invention succeeded in producing a large amount of IGF-I by using the following essential steps. Step 1 A process for the production of a gene coding for IGF-I. This process is optionally followed by a process for the production of fused IGF-I gene, i.e. a gene coding for IGF-I fused with a protective peptide which comprises linking a gene coding for a protective peptide with IGF-I gene with or without a linker upstream of said IGF-I gene. Suitable "linker" may include a gene coding for several amino acids and having a suitable restriction enzyme recognition sites to link a protective peptide upstream of IGF-I gene, and the "linker" per se constructs said protective peptide. The most suitable "linker" is the ones as exemplified hereinafter. Suitable "fused IGF-I, i.e. IGF-I fused with a protective peptide" is the ones as illustrated and exemplified hereinafter in the Examples. Step 2 A process for the production of an expression vector which comprises inserting a promoter gene and a gene coding for fused IGF-I into a plasmid. The most suitable "expression vector" is plasmid pSdM1-322trp and pLHSdMmtrp, The most suitable "plasmid" is pBR322. Step 3 A process for the production of a transformant which comprises transforming a host organism with said expression vector. Suitable "host organism" is Escherichia (hereinafter referred to as E .) coli (e. g. E . coli HB101, etc.) Step 4 A process for the production of fused IGF-I which comprises culturing said transformant in a suitable medium. Step 5 A process for isolation of fused IGF-I from host organism cells. Step 6 (optional) A process for the production of IGF-I which comprises subjecting said fused IGF-I to elimination reaction of the protective peptide. The "protective peptide" in the term "fused IGF-I, i.e. IGF-I fused with a protective peptide" is used for protecting IGF-I from degradation by protease in the cells of a host organism, and is removed by elimination reaction of said fused IGF-I. Namely, said fused IGF-I is an intermediate for preparing IGF-I by elimination reaction, so said protective peptide can be any eliminable protective peptide derived from natural or synthetic protein, natural or synthetic peptide, or a fragment thereof. Suitable "fused IGF-I" is IGF-I fused with a protein peptide through methionine of the protein peptide. Suitable agent used in this elimination reaction is cyanogen bromide; In this step, when the protein peptide is fused with IGF-I through methionine of the protein peptide, fused IGF-I can be converted to IGF-I by elimination reaction with cyanogen bromide in high yield. The present elimination reaction can be conducted under mild conditions in a conventional solvent which does not adversely affect the reaction. From the above amino acid sequence of IGF-I, a corresponding nucleotide sequence has been invented, subject to a number of specific non-obvious criteria. The IGF-I gene has been cloned by inserting it into a known plasmid, as a cloning vector. The IGF-I gene has been excised from the recombinant plasmid, and then inserted into a plasmid specifically designed to maximize expression of the IGF-I gene under the control of a promoter. A structural gene coding for a protective peptide is inserted into the recombinant plasmid upstream of and adjacent to said IGF-I gene. The present invention is illustrated in detail hereinafter. [1] Preparation and cloning of a IGF-I gene: (1) Preparation of a IGF-I gene: From the above amino acid sequence, because of the diversity of the genetic code, it is possible to predict numerous nucleotide sequences which would code for the IGF-I. In the inventive determination of an optimum sequence from the large number of possibilities, several non-obvious criteria have been observed. Firstly, trinucleotide codons should be used which are acceptable in a host organism to be used. Secondly, it should be desirable to have different restriction enzyme recognition sites at the terminal of the molecule so as to allow insertion into plasmid in a desired orientation. Moreover, it should be decided to select sites which will be allowed to use well known cloning vectors. Thirdly, the synthesis should not be unnecessarily complicated, and illegitimate cross-hybridization should be minimized in order to facilitate gene assembly, so that stable off-diagonal interactions might be avoided as far as possible. The one of the preferred sequence selected for the coding for portion of the IGF-I gene can be shown as follows: In the sequence in this specification A, G, C and T mean the formula: respectively, and 5'-terminal A, G, C and T mean the formula: respectively, and 3'-terminal A, G, C and T mean the formula: respectively. Considering the above-mentioned criteria, particularly in consideration of the second criteria mentioned above, the following slightly longer sequence can be selected. In fact, as a suitable embodiment of this invention, EcoRI and BamHI sites can be selected and introduced at the 5' and 3' ends, respectively. Further, a methionine codon (ATG) was inserted upstream of and adjacent to the N-terminal amino acid codon of IGF-I, and two stop codons (TGA and TAG) were inserted downstream of and adjacent to the C-terminal codon. The present application also discloses a process for the production of such a gene characterized in that it comprises hybridization and ligation of a number of the corresponding oligonucleotide blocks. (i) Synthesis of oligonucleotides: It was in fact decided to synthesize a molecule having the above expanded sequence by making 30 synthetic oligonucleotides, which will hybridized and ligated in pre-determined stage to give the double-stranded nucleotide sequence, mentioned above. In the specification about the synthesis of oligonucleotides in this specification, following abbreviations are used. Ap, Gp, Cp and Tp mean the formula: respectively, and 3'-terminal A, G, C and T mean the formula: respectively, and A Bz po , G iB po, C Bz po , Tpo and Ac Upo mean the formula: respectively, and DMTr is dimethoxytrityl, B is a base selected from adeninyl, guaninyl, cytosinyl and thyminyl (for convenience, protecting group are not shown), U is uracyl, Ac is acetyl, m is an integer of 1 or 2, and n is an integer of 1 to 12. The oligonucleotides are as follows: The methods of building up oligonucleotides from smaller units by successive coupling reactions. The successive coupling reaction is shown in Fig. 1. Mono(or di, or tri)mer (I) can be prepared by the Hirose's method [T. Hirose, PROTEIN, NUCLEIC ACID AND ENZYME ISSN, 25 , 225(1980), published in Japan], and coupling can be carried out on cellulose by a phosphotriester method [R. Crea et al , Nucleic Acid Research 8 , 2331(1980) and M. L. Duckworth et al , Nucleic Acid Research, 9 , 1691(1981)]. Particularly, the synthetic methods will now be illustrated with reference to the synthesis of the hexadecanucleotide HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH (G1) described in Example 1. The flow chart of the synthesis of the hexadecanucleotide G1 is shown in Fig. 2. (ii) Hybridization and ligation of chemically synthesized oligonucleotide: The oligonucleotides are hybridized and ligated in a series of steps, in order to minimize the possibilities for undesirable interactions as shown in Fig. 3. In Fig. 3, an oligonucleotide is illustrated with ( means 5'-phosphorylated end), and blocked oligonucleotides are illustrated, for example, Ligation is conducted in the presence of T4 DNA ligase. Oligonucleotides A1, B1 and A2; C1, B2 and C2; D1, E1 and D2; F1, E2, and F2; G1, H1, and G2; I1, H2 and I2; J1, K1 and J2; L1, K2 and L2; M1, N1 and M2 and O1, N2 and O2 were hybridized and ligated to give Blocks 1 to 10, respectively. In this case Blocks 1 and 10 which were obtained from oligonucleotides A1, B1 and A2, and O1, N2 and O2, respectively, hybridized and ligated each other to form dimers. Blocks 2 and 3; 4 and 5, 6 and 7, 8 and 9 were hybridized and ligated to give Blocks 11, 12, 13 and 14, respectively. Blocks 11 and 12; 13 and 14 were hybridized and ligated to form Blocks 15 and 16, respectively. Blocks 1, 15, 16 and 10 were hybridized and ligated, and thus obtained ligated mixture was cleaved by EcoRI and BamHI to give an objective polynucleotide IGF-I gene. (2) Molecular cloning of the IGF-I gene: In order to clone the IGF-I gene, it is inserted into an appropriate plasmid, cloning vector, having suitable enzyme recognition sites in which the IGF-I gene can be inserted. As a suitable embodiment of this invention IGF-I gene synthesized for the expression in E . coli was inserted into a plasmid originated in E . coli (e. g. pBR322, etc.) and cloning was conduced. For example, in case using a plasmid pBR322 (commercially available) having EcoRI and BamHI sites, as shown in Fig. 4, the plasmid was cleaved by EcoRI and BamHI. In this case the plasmid has ampicillin resistance code (it is indicated by Amp) on the longer fragment when cleaved by EcoRI and BamHI, and tetracycline resistance code (it is indicated by Tet) vanishes in consequence of the cleavage of BamHI site. The longer fragment of EcoRI, BamHI-cleaved plasmid pBR322 was purified by electroelution, hybridized and ligated with a large excess of the IGF-I gene using T4 DNA ligase. Thus obtained mixture was transformed into E . coli HB101 (ATCC 33694). The plasmid was isolated from one of the obtained several ampicillin resistant and tetracycline sensitive transformants and confirmed to contain IGF-I gene by digestion with restriction enzyme and electrophoresis. This process is shown in Fig. 4. Thus obtained plasmid is named as plasmid pSdM1. (3) Sequence of IGF-I gene in plasmid pSdM1: Maxam-Gilbert method can be used. For the sequencing of IGF-I gene, plasmid pSdM1 was digested with EcoRI and then treated with AMV reverse transcriptase in the presence of α-³²P-ATP. The linear plasmid labeled with ³²P was digested with BamHI to give two fragments (224 bp, 4.0 kbp). The smaller fragment (224 bp) was analysed by usual Maxam-Gilbert method [A. Maxam and W. Gilbert, Proc. Natl. Acad. Sci. USA 74 , 560 (1977)]. On the other hand, plasmid pSdM1 was digested with BamHI firstly, and then labeled with ³²P as described above. The linear plasmid was digested with EcoRI to give two fragments (224 bp, 4.0 kbp). The smaller fragment (224 bp) was analysed by Maxam-Gilbert method. The results of sequencing from both side of IGF-I gene were agreed with the designed IGF-I gene. [2] Preparation and cloning of a promoter gene: To obtain fused IGF-I from a host organism, a promoter gene was designed. A promoter gene obtained by such a criteria is inserted into a plasmid in a style that the promoter gene is located upstream of and adjacent to a gene coding for IGF-I or fused IGF-I. As a suitable embodiment of this invention a synthetic trp promoter I gene or synthetic trp promoter II gene were prepared. (1) Preparation and cloning of a synthetic trp promoter I gene: It was in fact decided to synthesize a molecule 107 bp by making 14 synthetic oligonucleotide blocks, which will be assemble by single-strand overlaps to give the complete double stranded nucleotide sequence. (i) Synthesis of oligonucleotides: The oligonucleotide blocks are as follows: The synthetic method will now be illustrated with reference to the synthesis of hexadecanucleotide HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH (G1) mentioned above. (ii) Ligation of chemically synthesized oligonucleotide: The oligonucleotides were hybridized and ligated according to a similar manner to that of a IGF-I gene as shown in Fig. 5. (iii) Molecular cloning of the synthetic trp promoter I gene: In order to clone the synthetic trp promoter I gene, the synthetic trp promoter gene is inserted to an appropriate plasmid having suitable enzyme recognition sites to which the synthetic trp promoter I gene can be inserted. As a suitable embodiment of this invention, cloning was conducted by using a plasmid pBR325 (commercially available) as shown in Fig. 6. The plasmid pBR325 was cleaved with EcoRI, and the synthetic trp promoter I gene was inserted thereto. Thus obtained plasmid is named plasmid pST-1. The plasmid pST-1 was transformed into E . coli HB101. (2) Preparation of synthetic trp promoter II gene: To insert the synthetic trp promoter I described above in a correct direction into a plasmid, following type of a synthetic promoter, synthetic trp promoter II, having a certain length of base pair chain following EcoRI site of synthetic trp promoter I and BamHI site at 3'-end was prepared. It was in fact decided to synthesize a molecule having 163 bp by making 22 synthetic oligonucleotide blocks, which will be assemble by single-strand overlaps to give the complete double-stranded nucleotide sequence. (i) Synthesis of oligonucleotides: Eight oligonucleotide was further synthesized. The synthetic method will now be illustrated with reference to the synthesis of hexadecanucleotide HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH (G1) mentioned above. (ii) Hybridization and ligation of chemically synthesized oligonucleotides: The oligonucleotide A to N and SA to SH were hybridized and ligated according to a similar manner to that of a IGF-I gene as shown in Fig. 7. (iii) Molecular cloning of synthetic trp promoter II gene: The synthetic trp promoter II gene was inserted into a plasmid. As a suitable embodiment of this invention, the synthetic trp promoter II was inserted into a plasmid pBR322 by cleaving the sites with EcoRI and BamHI as shown in Fig. 8. Thus obtained plasmid is named as plasmid pTrpEB7. [3] Preparation and cloning of protein peptide LH gene: As a suitable example of a protective peptide which can be fused with IGF-I, protein peptide LH has been prepared. (1) Preparation of protein peptide LH gene: It was in fact decided to synthesize a molecule 233 bp by making 32 synthetic oligonucleotide blocks, which will be assemble by single-strand overlaps to give the complete double stranded nucleotide sequence. (i) Synthesis of oligonucleotides: The oligonucleotide blocks are as follows: (ii) Hybridization and ligation of chemically synthesized oligonucleotides: The oligonucleotides a1 to 13 were hybridized and ligated according to a similar manner to that of IGF-I gene as shown in Fig. 9. (2) Molecular cloning of protein peptide LH gene: Protein peptide LH gene was inserted into a plasmid. As a suitable embodiment of this invention, protein peptide LH gene was inserted into a plasmid pBR322 by cleaving the sites with EcoRI and BamHI as shown in Fig. 10. Thus obtained plasmid is named as plasmid pLH107. [4] Construction of expression vector of IGF-I: IGF-I gene is inserted to a plasmid containing a promoter gene, and IGF-I gene is transformed into a host organism. As a suitable embodiment of this invention, the following recombinant plasmids were established to express IGF-I gene in E . coli . (1) Construction of recombinant plasmid pSdM1trp: Trp promoter plasmid pST-1 prepared above was digested with EcoRI and IGF-I gene was inserted to the resulted large fragment. Thus obtained recombinant plasmid was named a plasmid pSdM1trp which was transformed into E . coli , for example E . coli HB101. This process is shown in Fig. 11. (2) Construction of recombinant plasmid pSdM1-322trp: Trp promoter plasmid pTrpEB7 was digested with EcoRI and BamHI, the resulted large fragment (4.1 kbp) was separated by agarose gel electrophoresis. On the other hand, the IGF-I gene was isolated from plasmid pSdM1, and ligated with the above promoter vector (4.1 kbp). The mixture was transformed into E . coli HB101. The plasmid was isolated from one of the obtained ampicillin resistant and tetracycline sensitive transformants, and confirmed to contain IGF-I gene by digestion with restriction enzyme and electrophoresis. Thus obtained plasmid is named as plasmid pSdM1-322trp and the E . coli containing the plasmid is named as E . coli F-3. This process is shown in Fig. 12. [5] Sequencing of IGF-I gene and a promoter gene: Maxam Gilbert method can be used. (1) Sequence of IGF-I gene and synthetic trp promoter I gene in plasmid pSdM1trp: Sequence of IGF-I and the synthetic trp promoter I in plasmid pSdM1trp was determined as a similar manner to that of plasmid pSdM1-322trp described below. (2) Sequence of IGF-I gene and synthetic trp promoter I gene in plasmid pSdM1-322trp: For sequencing of IGF-I and the synthetic trp promoter I gene, plasmid pSdM1-322trp was digested with EcoRI and treated with BAP (bacteria alkaline phosphatase), and then treated with T4 polynucleotide kinase in the presence of γ-³²P-ATP. The labeled DNA was digested with HinfI to give two fragments (110 bp and 480 bp). These fragments were analyzed by Maxam-Gilbert method. (A. Maxam and W. Gilbert, Proc. Natl. Acad. Sci. USA 74 , 560 (1977)). The resulting sequence coincided with the designed sequence of IGF-I gene and the synthetic promoter I gene. [6] Construction of expression vector of fused IGF-I: A gene coding for fused IGF-I which comprises linking a gene coding for a protective peptide with IGF-I gene with or without a linker upstream of the IGF-I gene was preapred. In this process, the following type of protein peptides is fused with IGF-I. Type I: a protein peptide having methionine as the last amino acid Thus obtained type of fused IGF-I is as follows. Type I: IGF-I fused with the protein peptide through methionine of the protein peptide The present invention also relates to expression vectors of a gene coding such a type of fused IGF-I. As a suitable embodiment of this invention, the following type of expression vector of a gene coding for IGF-I fused with protein peptide LH is prepared. The present invention also relates to a process for the invention of such a gene which is constructed by linking a gene coding for a protective peptide with the IGF-I gene upstream of said IGF-I gene with or without a linker. (1) Construction of expression vector of protein peptide LH gene: Protein peptide LH gene is inserted into a plasmid containing a promoter gene, and protein peptide LH gene is transformed into a host organism. As a suitable embodiment of this invention, the following recombinant plasmid was established to express protein peptide LH gene in E . coli . Trp promoter II plasmid pTrpEB7 was digested with EcoRI and BamHI, the resulted large fragment (4.1 kbp) was separated by agarose gel electrophoresis. On the other hand, protein peptide LH gene was isolated from plasmid pLH107, and ligated with the above promoter vector (4.1 kbp). The mixture was transformed into E . coli HB101. The plasmid was isolated from one of the obtained ampicillin resistant and tetracycline sensitive transformants, and confirmed to contain protein peptide LH gene by digestion with restriction enzyme and electrophoresis. Thus obtained plasmid is named as plasmid pLHtrp. This process is shown in Fig. 13. (2) Construction of expression vector of IGF-I fused with protein peptide LH: IGF-I gene is inserted into a plasmid containing protein peptide LH gene downstream of and adjacent to a promoter gene. As a suitable embodiment of this invention, the following recombinant plasmid was established to express IGF-I fused with protein peptide LH gene in E . coli . In this stage, one type of linker was inserted upstream of and adjacent to IGF-I gene. (a) Construction of expression vector of a gene coding for IGF-I fused with protein peptide LH (Type I): A plasmid pLHtrp prepared above was digested with HindIII and BamHI, the resultant large fragment was separated by preparative agarose gel electrophoresis. On the other hand, IGF-I gene was isolated from plasmid pSdM1 prepared above with EcoRI and BamHI digestion and oligonuclotides m1 and m2 were ligated upstream of and adjacent to it as a linker. Thus obtained IGF-I gene with linker was ligated with the above large fragment of plasmid pLHtrp. The mixture was transformed into E . coli HB101. The plasmid was isolated from one of the obtained ampicillin resistant and tetracycline sensitive transformants, and confirmed to contain a gene coding for IGF-I fused with protein peptide LH (Type I) by digestion with restriction enzyme and electrophoresis. Thus obtained plasmid is named as plasmid pLHSdMmtrp. This process is shown in Fig. 14. Thus obtained gene coding for IGF-I fused with protein peptide LH (Type I) is as follows: and a gene coding for IGF-I fused with protein peptide LH (Type I) is as follows: [7] Expression of the IGF-I gene in a host organism: For the expression of the IGF-I gene, thus obtained plasmid having a promoter gene and IGF-I gene is transformed into a host organism, and then the host organism having the plasmid is the cultured in nutrient medium containing sources of assimilable carbon and nitrogen under aerobic conditions (e. g. shaking culture, submerged culture, etc.). The preferred sources of carbon in the nutrient medium are carbohydrates such as glucose, fructose, sucrose, glycerin, starch and the like. Other sources which may be included are xylose, galactose, maltose, dextrin, lactose and the like. The preferred sources of nitrogen are yeast extract, peptone, gulten meal, cottonseed flour, soybean meal, corn steep liquor, dried yeast, wheat germ, etc., as well as inorganic and organic nitrogen compounds such as ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea, amino acid and the like. The carbon and nitrogen sources, though advantageously employed in combination, need not be used in their pure form, because less pure materials which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use. When desired, there may be added to the medium mineral salts such as calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, magnesium salts, copper salts and the like. Agitation and aeration of the culture mixture may be accomplished in a variety of ways. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermentor, by various pumping equipment or by the passage of sterile air through the medium. Agitation may be effected by passing sterile air through the fermantition mixture. The fermentation is usually conducted at a temperature between about 20°C and 42°C, preferably 35-38°C, for a period of several hours to 50 hours. Thus produced IGF-I or fused IGF-I can be recovered from the cultured medium by conventional means which are commonly used for the recovery of other known biologically active substances. In general, IGF-I or fused IGF-I produced are found in the cells of host organisms, and accordingly IGF-I or fused IGF-I can be separated from the cells, which is obtained by filtering or centrifuging the cultured broth, by a conventional method such as concentration under reduced pressure, lysis such as sonication, HPLC, lyophilization, pH adjustment, treatment with resin (e.g. anion or cation exchange resin, non-ionic adsorption resin), treatment with a conventional adsorbent (e.g. activated carbon, silicic acid, silica gel, cellulose, almina), gel filtration, crystallization, and the like. (1) Expression of the IGF-I gene in E . coli using plasmid pSdM1trp An overnight culture of E . coli HB101 containing pSdM1trp in L broth was diluted in M9 medium lacking tryptophan, and the cells were incubated at 37°C for 3 hours under the condition of β-indoleacrylic acid induction. Detection of IGF-I production was carried out using a radioimmunoassay (hereinafter referred to RIA) with the antibody of IGF-I fragment (26-46) according to N. Yanaihara's method [N. Yanaihara et al , Peptide Hormones in Pancreas 3 , 28(1983)]. (2) Expression of the IGF-I gene in E . coli using plasmid pSdM1-322trp An overnight culture of E . coli HB101 containing plasmid pSdM1-322trp in L broth was diluted in M9 medium lacking tryptophan, and the cells were incubated at 37°C for 3 hours under the condition of β-indoleacrylic acid induction. Detection of IGF-I production was carried out using RIA with the antibody of IGF-I fragment (26-46) according to N. Yanaihara's method. [8] Expression of a gene coding for fused IGF-I in a host organism: (1) Expression of a gene coding for IGF-I gene fused with protein peptide LH (Type I) in a host organism: For the expression of a gene coding for IGF-I fused with protein peptide LH (Type I), thus obtained plasmid having a promoter gene and a gene coding for IGF-I fused with protein peptide LH (Type I) is transformed into a host organism, and then the host organism having the plasmid is cultured in a suitable medium. IGF-I fused with protein peptide LH (Type I) is isolated from the resulting culture broth. (i) Expression of a gene coding for IGF-I fused with protein peptide LH (Type I) in E . coli using plasmid pLHSdMmtrp: An overnight culture of E . coli HB101 containing pLHSdMmtrp in L broth was diluted in M9 medium lacking tryptophan, and the cells were incubated at 37°C for 3 hours under the condition of β-indoleacrylic acid induction. Detection of the fused IGF-I production was carried out using a radioimmunoassay (hereinafter referred to as RIA) with the antibody of IGF-I fragment (26-46) according to N. Yanaihara's method [N. Yanaihara et al , Peptide Hormones in Pancreas 3 , 28(1983)]. (ii) Isolation of IGF-I fused with protein peptide LH (Type I): The culture fluid was centrifuged to give a wet cell paste, and the cells were lysed by sonication. The pellet was collected by centrifugation and then dissolved in 8M urea solution containing 0.1 M dithiothreitol (hereinafter referred to as DTT). After centrifugation the solution was purified by S 300 column chromatography. Active fractions detected by RIA were collected and dialysed to give protein which contains a desired component. The fused IGF-I was detected a normal position (15500) on polyacrylamide gel electrophoresis. Thus obtained IGF-I fused with protein peptide LH (Type I) is as follows: [9] Conversion of fused IGF-I to IGF-I and isolation of IGF-I: Thus obtained fused IGF-I can be converted to IGF-I by elimination reaction of the protective peptide. This elimination reaction can be conducted in accordance with a conventional method used in the field of peptide chemistry. Suitable elimination reaction can be selected according to the type of fused IGF-I. Suitable agent used in this elimination reaction is cyanogen bromide; This elimination reaction is usually carried out under mild conditions in a conventional solvent which does not adversely affect the reaction. The reaction temperature is not critical and the reaction is usually conducted from cooling to warming. The elimination reaction which can be applied to the type of fused IGF-I is hereinafter described in detail. (1) Elimination of the protein peptide from IGF-I fused with the protein peptide through methionine of the protein peptide: IGF-I fused with a protein peptide through methionine of the protein peptide can be converted to IGF-I by elimination reaction with cyanogen bromide. In this case, although IGF-I has methionine in the 59th position of the amino acid sequence, the cleavage at the amide bond linking the 59th methionine and the 60th tyrosine of IGF-I follows the cleavage at the amide bond linking the methionine in front of the 1st amino acid of IGF-I and the 1st amino acid of IGF-I, glycine. This phenomena, the order of cleavage at the bond neighboring methionine has been discovered by the inventors for the first time. According to this phenomena, protein peptide can be removed easily by elimination reaction from said fused IGF-I with cyanogen bromide if the suitable condition is selected. This reaction is usually carried out under mild conditions in a conventional solvent which does not adversely affect the reaction. The reaction temperature is not critical and the reaction is usually carried out from cooling to warming. Elimination of protein peptide LH from fused IGF-I with protein peptide LH through methionine of protein peptide LH (Type I): The fused IGF-I was treated with cyanogen bromide in 60% formic acid at 25° C for 3 hours. After lyophilization the residue was dissolved in 8 M urea solution containing 50 mM 2-mercaptoethanol and dialyzed to give a crude mixture of reduced IGF-I. The mixture was purified by cationic ion exchange chromatography (CM52), and active fractions detected by RIA were collected and dialysed. The dialysed fraction was applied on high performance liquid chromatography to give a pure reduced IGF-I. The reduced IGF-I was converted to oxidized IGF-I by a usual manner of refolding. The purified IGF-I showed a single band on polyacrylamide gel electrophoresis (PAGE), and the IGF-I was supperimposed with authentic IGF-I gifted by Dr. Humbel on HPLC. The amino acid sequence of IGF-I was determined by the conbination of Edman's method and carboxypeptidase method. The IGF-I showed biological activity in [³H]-thymidine incorporation assay of mouse BALB/c 3T3 cells. [10] Radioimmunoassay of IGF-I: RIA of IGF-I was followed the method established by N. Yanaihara [N. Yanaihara et al: Peptide Hormones in Pancreas 3 , 28(1983)]. With 0.1 ml of the above sample or standard sample (IGF-I fragment (26-46)) sample buffer [0.5% BSA in 0.01M PBS, 0.025 M EDTA (pH 7.4) (0.4 ml)], rabbit antiserum (0.1 ml) of IGF-I (26-46) and ¹²⁵I-IGF-I (26-46) (0.1 ml) were mixed. The mixture was allowed to stand for 48 hours at 4°C, and then added with rabbit serum (0.1 ml), rabbit γ-globulin antiserum (0.1 ml) and 5% PEG6000 (0.9 ml). After standing for additional 2 hours at 4°C the pellet was collected by centrifugation (3 krpm, 4°C, 30 minutes), and measured radio activity by γ-counter. The content of IGF-I was calculated from this radio activity. [11] Biological assay of IGF-I: Mouse BALB/c 3T3 embryofibroblasts (clone A31) were trypsinized and resuspended at a concentration of 10⁵ cells/ml in Dulbecco-Vogt Modified Eagle's medium containing 10% New Born Calf Serum and 25 mM N-(2-hydroxyethyl)piperazine-N'-2-ethanesulfonic acid (HEPES). Aliquots of 100 µl were plated into 0.3 cm² wells(96 well-microtiter plate, Costor). Three to four days after the cells reached confluence (5-7 days after initial plating) the sent medium was removed and the culture was washed three times and then 0.2 µCi/well [³H]thymidine (0.67 Ci/mmole) plus test samples were added. After incubation of 24 hours, the medium was removed and cells were washed with PBS and trypsinized for determination of radioactivity. Cells were trapped in glass filters by use of semi automatic multiple cell harvester (LAVO MASH, LABO SCIENCE). Incorporated [³H]thymidine was counted in 8 ml of Aquazol 2 (New England Nuclear) using a Packard Tri-Carb Liquid Scintillation Counter. The following examples are given for the purpose of illustrating the present invention. Example 1 Synthesis of HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH (G1) (1) Synthesis of DMTrOTpoA Bz poTpoG iB po Ac Upo-cellulose: i) Preparation of HOG iB po Ac Upo-cellulose: To a suspension of DMTrOG iB po Ac Upo-cellulose (130.4 mg, 4.59 µmole ) (prepared by R. Crea's method ii) Preparation of DMTrOTpoA Bz poTpo⁻: DMTrOTpoA Bz poTpo-CE (39.9 mg, 23.0 µmole) was treated with Et₃N-CH₃CN (1:1 v/v, 5 ml) at room temperature for 1 hr. The phosphodiester trimer (DMTrOTpoA Bz poTpo⁻) so obtained was dried, water being separated as the pyridine azeotrope (0.5 ml, 2 x 1 ml). ) in methanol/CHCl₃ (1:9 v/v, 5.0 ml). TCA/CHCl₃ (2:8 w/v , 5.0 ml) was added under ice cooling, and the mixture was stirred at O°C for 10 min. After being washed with CHCl₃ (2 ml) and methanol (6.0 ml), successively, on the filter, the cellulose adduct (HOG iB po Ac Upo-cellulose) was dried, water being separated as the pyridine (2 ml) azeotrope. iii) Coupling: The trimer (DMTrOTpoA Bz poTpo⁻) was mixed with the cellulose adduct (HOG iB po Ac Upo-cellulose) in a 10 ml round-bottom flask. The mixture was dried, water being separated as the pyridine azeotrope (2 x 1 ml) and finally resuspended in anhydrous pyridine (1 ml). Mesitylen sulfonyl nitrotriazolide (MSNT) (68.0 mg, 230 µmole) was added to the suspension and the mixture was stirred at room temperature for 1 hr. And then pyridine was added to the reaction vessel and cellulose adduct was recovered by centrifugation (3,000 rpm, 2 min). iv) Acetylation of unreacted 5'hydroxyl groups: The cellulose adduct obtained as above was suspended in a solution of pyridine-acetic anhydride (10:1 v/v, 5.5 ml) and stirred at room temperature for 30 min. The cellulose-product (113.9 mg) was obtained by repeated centrifugation (3,000 rpm, 2 min) in pyridine (5 ml), washing with methanol (15 ml) and drying in vacuo at room temperature for 30 minutes. The cellulose adduct (DMTrOTpoA Bz poTpoG iB po Ac Upo-Cellulose) can use for the next coupling step. (2) Synthesis of DMTrOG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose. DMTrOG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose was synthesized from DMTrOTpoA Bz poTpoG iB po Ac Upo-cellulose (113.9 mg) and DMTrOG iB poG iB poC Bz po-CE (43.7 mg) according to similar conditions as above. (3) Synthesis of DMTrOA Bz poC Bz poC Bz poG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-Cellulose: DMTrOA Bz poC Bz poC Bz poG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose (105.8 mg) was synthesized from DMTrOG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose (109.5 mg) and DMTrOA Bz poC Bz poC Bz po-CE (44.0 mg) according to similar conditions. (4) Synthesis of DMTrOC Bz poC Bz poG iB poA Bz poC Bz poC Bz po-G iB po-G iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose: DMTrOC Bz poC Bz poG iB poA Bz poC Bz poC Bz poG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose (94.5 mg) was synthesized from DMTrOA Bz poC Bz poC Bz poG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose (105.8 mg) and DMTrOC Bz poC Bz poG iB po-CE (43.5 mg) according to similar conditions. (5) Synthesis of DMTrOA Bz poA Bz poA Bz poC Bz poC Bz poG iB poA Bz poC Bz poC Bz poG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose: DMTrOA Bz poA Bz poA Bz poC Bz poC Bz poG iB poA Bz poC Bz poC Bz poG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose (90.4 mg) was synthesized from DMTrOC Bz poC Bz poG iB poA Bz poC Bz poC Bz poG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-Cellulose (94.5 mg) and DMTrOA Bz poA Bz poA Bz po-CE (45.1 mg) under the similar conditions. At this final process, unreacted 5'-hydroxy group was not necessary to protect with an acetyl group. (6) Synthesis of HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH: DMTrOA Bz poA Bz poA Bz poC Bz poC Bz poG iB poA Bz poC Bz poC Bz poG iB poG iB poC Bz poTpoA Bz poTpoG iB po Ac Upo-cellulose (90.4 mg) was treated with 0.5 M N,N,N',N'-tetramethylguanidinium pyridine 2-aldoximate (in dioxane-H₂O (1:1 v/v, 1 ml)) at 20°C for 20 hrs in a sealed tube. To the reaction mixture 28% (w/w) aqueous ammonia (12 ml) was added, and the mixture was heated at 60°C for 2 hrs. The solid cellulose was removed by filtration and washed with water (10 ml). The filtrate and washed solution were evaporated to dryness, and the residue was treated with 80% aqueous acetic acid (25 ml) at room temperature for 15 mins. After removal of the solvents, the residue was dissolved in 0.1 M triethylammonium carbonate buffer (pH 7.5, 25 ml) was washed with diethylether (3 x 25 ml). Aqueous layer was evaporated to dryness and the residue was dissolved in 0.1 M triethylammonium carbonate buffer (pH 7.5, 2 mins) to yield crude HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH in the solution. (7) Purification of HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH i) First purification of the crude product was performed by column chromatography on Biogel P2 (24 x 2.6 cm ID). The fractions corresponding to the first eluted peak (50 mM NH₄OAc, 0.1 mM EDTA, 1 ml/min) were collected and freeze-dried to give the first purified product. ii) Second purification of the first purified product was performed by HPLC on CDR-10 (25 cm x 4.6 mm ID) using a linear gradient of 1M NH₄OAc-10% (v/v) aqueous ethanol to 4.5 M NH₄OAc-10% (v/v) aqueous ethanol (80 min, 1 ml/min, 60°C) to give the second purified product. iii) Third purification of the second purified product was performed by reverse phase HPLC (Rp-18-5µ(x77), 15 cm x 4mm ID) using a linear gradient of 0.1 M NH₄OAc to 0.1 M NH₄OAc 15% (v/v) aqueous CH₃CN (40 min, 1.5 ml/min, room temperature) to give the final purified product (HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH). (8) Analysis of oligonucleotide: (HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH) i) Digestion by phosphodiesterase: The mixture of HOApApApCpCpGpApCpCpGpGpCpTpApTpGOH (5 µg, 61.7 µl), 0.2 M MgCl₂ (10 µl), 0.2 M Tris-HCl (pH 8.5) (10 µl) and 0.1 mM EDTA in an aqueous solution (13.3 µl) was treated with phosphodiesterase (5 unit, 5 µl) at 37°C for 20 min, and then heated at 100°C for 2 min. ii) Analysis by HPLC: The oligonucleotide in the reaction mixture was analyzed by HPLC (CDR-10, 25 cm x 4.6 mm ID) using a linear gradient of water to 2.0 M NH₄OAc (pH 3.4) (40 min, 1.5 ml/min, 60°C). From each peak area observed, its nucleotide composition was determined comparing with area of a standard sample. Calcd: pC OH 5,000, pA OH 4,000, pT OH 2,000, pG OH 4,000 Observed: pC OH 4,767, pA OH 4,127, pT OH 2,054, pG OH 4,052 Example 2 Synthesis of oligonucleotides (A1, A2, B1, B2, C1, C2, D1, D2, E1, E2, F1, F2, G2, H1, H2, I1, I2, J1, J2, K1, K2, L1, L2, M1, M2, N1, N2, O1 and O2): Following oligonucleotides were prepared by a similar manner to that of G1 described in Example 1. Example 3 Synthesis of oligonucleotides (a1, a2, a3, a4, a5, a6, b1, b2, b3, b4, b5, b6, c1, c2, c3, c4, c5, c6, d1, d2, d3, d4, d5, d6, e1, e2, e3, e4, e5, l1, l2 and l3): Following oligonucleotides were prepared by a similar manner to that of G1 described in Example 1. Example 4 Synthesis of oligonucleotides (m1, m2, LA, LB, LC and LD): Following oligonucleotide (m1 and m2) were prepared by a similar manner to that of Example 1. Example 5 Synthesis of oligonucleotides (A, B, C, D, E, F, G, H, I, J, K, L, M and N): Following oligonucleotides were prepared by a similar manner to that of Example 1. Example 6 Synthesis of oligonucleotides (SA, AB, SC, SD, SE, SF, SG, and SH): Example 7 Preparation of IGF-I gene: Aliquots of each oligonucleotides (A1-O1) (0.4 nM) were phosphorylated with 4 units of T4 polynucleotide kinase (made by BRL) in 100 µl of a solution containing 74 mM Tris-HCl (pH 7.6), 10 mM DTT, 1.6 mM mercaptoethanol, 10 mM MgCl₂ and 0.5 mM ATP for 20 minutes at 37°C. After the reaction was completed, the enzyme in the reaction mixture was deactivated by incubation at 100°C for 5 minutes. Ligation of the phosphorylated oligonucleotides was carried out as shown in Fig. 3 to give firstly fragment ten blocks and ultimately the IGF-I gene for cloning. Ligations were carried out with T4 DNA ligase (7 units) in a solution containing 100 mM ATP (0. 5 µl) for 23 hours at 4°C (standard conditions). The ligation products of oligonucleotides in each step were identified by staining with ethidium bromide following electroelution on a 2-16% gradient PAGE in tris-EDTA buffer. Example 8 Molecular cloning of the IGF-I gene: Plasmid pBR322 was digested with BamHI and EcoRI restriction endonucleases. Reaction was terminated by heating at 65°C for 5 minutes and the fragments separated by electrophoresis on a 0.5% agarose gel. The 3985 bp large fragment from pBR322 was recovered and ligated with T4 DNA ligase for 18 hours at 12°C to the 224bp IGF-I gene. The ligated mixture was transformed into E . coli HB101 by Kushner's method and ampicillin resistant transformants were selected on the plate containing tetracycline (25 µg/ml). Plasmid DNA isolated from one of five clones resistant to ampicillin and sensitive to tetracycline was digested with EcoRI and BamHI and compared with appropriate size markers. The expected 224 bp IGF-I fragment was generated. This plasmid which was characterized by complete nucleotide sequencing of the IGF-I gene was named pSdM1 and was used for the construction of expression vector. Example 9 Construction of the synthetic tryptophan promoter gene I: Each oligonucleotides (B-M) of block I, II, III were phosphorylated with T4 polynucleotide kinase and then ligated with T4 DNA ligase as described above. These blocks (I-III) and unphosphorylated oligonucleotides (A, N) were condensed successively. The last ligation product was purified by preparative 7.5% PAGE to give the 107 bp synthetic trp promoter I gene. Example 10 Molecular cloning of the synthetic trp promoter I gene Plasmid pBR325 was digested with EcoRI and then linear pBR325 was ligated with the synthetic trp promoter I gene prepared above. The transformants of E . coli HB101 by the above ligation mixture were screened on the plates contained antibiotics to give four R Amp S Cm colonies. The plasmids obtained from four colonies were digested with HpaI, respectively. The fragments obtained from these plasmids by HindIII and EcoRI digestion were compared with the fragments of pBR325 by HindIII and EcoRI digestion. One of four plasmids has the correct directed promoter gene (synthetic trp promoter I gene) and the other were inserted in reverse direction. Example 11 Construction and cloning of the synthetic trp promoter II gene: Trp promoter II gene was constructed by the same method as described previously. The synthetic gene was ligated with EcoRI, BamHI fragment of pBR322 and then E . coli HB101 was transformed with the ligation product. The plasmid obtained from the transformant of R Amp and S Tet was digested with HpaI to confirm a band (4.1 kbp), and then digested with BamHI to confirm a band of 90 bp on PAGE. Moreover, the fragment of 56 bp by EcoRI-BamHI digestion was confirmed by the comparison with size marker on PAGE. This plasmid was named pTrpEB7 and used construction of expression vector. Example 12 Construction of IGF-I expression vector (pSdM1-322trp): Trp promoter II vector (pTrpEB7) was digested with EcoRI and BamHI to give a large fragment (4.1 kbp) by PAGE. This fragment was ligated with the IGF-I gene prepared from a plasmid pSdM1. The ligated mixture was transformed into E . coli HB101 and ampicillin resistant and tetracycline-sensitive transformants were selected. The obtained plasmid pSdM1-322trp was digested with EcoRI and BamHI to confirm the IGF-I gene (224bp) on 7.5% PAGE. Example 13 Sequencing of IGF-I gene and synthetic trp promoter I gene: For the sequencing of IGF-I gene and synthetic trp promoter I gene by Maxam-Gilbert method, plasmid pSdM1-322trp was digested with EcoRI and treated with bacteria alkaline phosphatase at 37°C for 1 hour. After phenol extraction and ethanol precipitation the plasmid was phosphorylated with T4 polynucleotide kinase in the presence of γ-³²P-ATP at 37°C for 1 hour, finally was digested with HinfI to afford two fragments (1100 bp, 480 bp). Each fragment was sequenced according to the manual of Maxam-Gilbert method [A. Maxam and W. Gilbert, Proc. Natl. Acad. Sci. USA 74 , 560(1977)]. The resulted sequence of IGF-I and synthetic trp promoter I gene agreed with that designed. Example 14 Expression of IGF-I gene: An overnight culture of E . coli F-3 (which is E . coli HB101 containing plasmid pSdM1-322trp) in L broth containing 20 µg/ml ampicilline was diluted 1 : 25 in M9 medium containing 0.2% glucose, 0.5% casamino acid (acid-hydrolyzed casein) and 50 µg/ml vitamine B1. β-indole acrylic acid was added to a final concentration of 10 µg/ml when A₆₀₀ was 0.4. Then the cells were incubated for 3 hours and collected by centrifugation (6 krpm, 4°C, 5 minutes). Cell were opened by sonication and cleared of debris by centrifugation. The supernatants were mixed with 3M acetic acid. The precipitate was removed by centrifugation (20 krpm, 4°C, 10 minutes), the supernatants were freeze-dried. For assay the sample was suspended in 4 ml of medium (0.01 M PBS, 0.025M EDTA, and 0.5% BSA) and adjusted at pH 7-8 with 0.1N NaOH. After removal of insoluble substance by centrifugation, the supernatants were stored at -20°C until assay. Example 15 RIA of IGF-I: The RIA of IGF-I was followed the method established by N. Yanaihara. With 0.1 ml of the above sample or standard sample (IGF-I fragment (26-46)) sample buffer [0.5% BSA in 0.01M PBS, 0.025 M EDTA (pH 7.4) (0.4 ml)], rabbit antiserum (0.1 ml) of IGF-I (26-46) and ¹²⁵I-IGF-I (26-46) (0.1 ml) were mixed. The mixture was allowed to stand for 48 hours at 4°C, and then added with rabbit serum (0.1 ml), rabbit γ-globulin antiserum (0.1 ml) and 5% PEG6000 (0.9 ml). After standing for additional 2 hours at 4°C the pellet was collected by centrifugation (3 krpm, 4°C, 30 minutes), and measured radio activity by γ-counter. The content of IGF-I was calculated from this radio activity. Example 16 Sequencing of IGF-I gene in plasmid pSdM1: For the sequencing of IGF-I gene, plasmid pSdM1 was digested with EcoRI and then treated with AMV reverse transcriptase (purchased from Seikagaku Kogyo Co., Ltd.) in the presence of α-³²P-ATP at 37°C for 30 minutes. The linear plasmid labeled with ³²P was digested with BamHI to give two fragments (224 bp, 4.0 kbp). The smaller fragment (224 bp) was recovered by preparative polyacrylamide gel electrophoresis and sequenced according to the manual of Maxam-Gilbert method. On the other hand, plasmid pSdM1 was digested with BamHI firstly and then labeled with ³²P as described above. The linear plasmid was digested with EcoRI to give two fragments (226 bp, 4.0 kbp). The smaller fragments (224 bp) was analyzed by Maxam-Gilbert method as above. The results of sequencing from both side of IGF-I gene were agreed with the designed IGF-I gene. Example 17 Preparation of protein peptide LH gene: Aliquots of each oligonucleotides (a2-12) (0.4 nM) were phosphorylated with 2.5 units of T4 polynucleotide kinase in 40 µl of a solution containing 50 mM Tris-HCl (pH 7.6), 20 mM DTT, 50 µg/ml BSA, 1 mM spermidine, 10 mM MgCl₂ and 2 mM ATP for 3 hours at 37°C. After the reaction was completed, the enzyme in the reaction mixture was deactivated by incubation at 100°C for 5 minutes. Ligation of the phosphorylated oligonucleotides and two oligonucleotides (a1 and 13) was carried out as shown in Fig. 7 to give firstly fragment six blocks and ultimately protein peptide LH gene (236 bp) for cloning. Ligation was carried out with T4 DNA ligase (5 units) in a solution containing 50 mM ATP (1 µl) for 5 hours at 16°C. The ligation products of oligonucleotides in each step were identified by staining with ethidium bromide following electroelution on a 2-16% gradient PAGE in Tris-EDTA buffer. Example 18 Molecular cloning of protein peptide LH gene: Protein peptide LH gene (236 bp) which synthesized as above was inserted into pBR 322 by a similar manner to that of Example 8. The plasmid (pLH107) obtained from E . coli HB101 transformant was characterized by restriction enzyme analysis to have protein peptide LH (236bp). Example 19 Construction of synthetic trp promoter II gene: Each oligonucleotides (B to SG) of block I', II', III' and IV' were phosphorylated with T4 polynucleotide kinase and then ligated with T4 DNA ligase as described above. These blocks (I' to IV') and unphosphorylated oligonucleotides (A and SH) were condensed successively. The last ligation product was purified by preparative 7.5% PAGE to give the 163 bp synthetic trp promoter II gene. Example 20 Cloning of the synthetic trp promoter II gene: Trp promoter II gene constructed in Example 19 was ligated with EcoRI, BamHI fragment of pBR322 and then E . coli HB101 was transformed with the ligation product. The plasmid obtained from the transformant of R Amp and S Tet was digested with HpaI to confirm a band (4.1 kbp), and then digested with BamHI to confirm a band of 90 bp on PAGE. Moreover, the fragment of 56 bp by EcoRI-BamHI digestion was confirmed by the comparison with size marker on PAGE. This plasmid was named pTrpEB7 and used for the construction of expression vector. Example 21 Construction of protein peptide LH expression vector (pLHtrp): Trp promoter II vector (pTrpEB7) prepared in Example 20 was digested with EcoRI and BamHI to give a large fragment (4.1 kbp) by preparative agarose gel electrophoresis. This fragment was ligated with protein peptide LH gene prepared from a plasmid pLH107 by EcoRI and BamHI digestion. The ligated mixture was transformed into E . coli HB101 to give ampicillin resistant and tetracycline sensitive transformants. The plasmid (pLHtrp) obtained from the transformant was digested with EcoRI and BamHI to confirm protein peptide LH gene (236 bp) on 7.5% PAGE. Example 22 Construction of IGF-I expression vector pLHSdMmtrp: Plasmid pSdM1 was digested with EcoRI and BamHI to give IGF-I gene (224 bp). On the other hand, oligonucleotide (m2) prepared in Example 4 (2) was phosphorylated with T4 polynucleotide kinase as described in Example 7. The phosphorylated oligonucleotide, oligonucleotide m1 prepared in Example 4 (1) and IGF-I gene (224 bp) were mixed and treated with T4 ligase in a solution containing 100mM ATP for 20 hours at 4°C. The ligation mixture was digested with BamHI and then purified by preparative PAGE to give IGF-I gene with linker (242 bp). The gene (242 bp) was ligated with the fragment obtained from pLHtrp by HindIII-BamHI digestion, and then the ligation mixture was transformed into E . coli HB101. The E . coli HB101 containing plasmid pLHSdMmtrp was named E . coli F-6 and deposited with Fermentation Research Institute Agency of Industrial Science and Technology (1-3, Higashi 1 chome Yatabe-machi Tsukuba-gun Ibaraki-ken 305, Japan) under deposit number of FERM P-7848 on September 17, 1984, and then converted to Budapest Treaty route of the same depository on February 28, 1985 under the new deposit number of FERM BP-729. The plasmid (pLHSdMmtrp) obtained from the transformant was digested with EcoRI and BamHI (198, 224 bp), HindIII and BamHI (242 bp), HpaI-BamHI (456 bp) to confirm the synthetic trp promoter I, protein peptide LH and IGF-I gene on 7.5% PAGE. Example 23 Expression of a gene coding for IGF-I fused with protein peptide LH (Type I) in E . coli F-6: An overnight culture of E . coli F-6 (which is E . coli HB101 containing plasmid pLHSdMmtrp) (FERM P-7848) in L broth containing 50µg/ml ampicillin was diluted 1:20 in M9 medium containing 0.2% glucose, 0.5% casamino acid (acid-hydrolyzed casein), 50 µg/ml vitamin B1 and 25 µg/ml ampicillin. β-Indole acrylic acid was added to a final concentration of 10µg/ml when A₆₀₀ was 0.5. Then the cells were incubated for 2 hours and collected by centrifugation (5 krpm, 4°C, 5 minutes). Example 24 Isolation and purification of IGF-I: (1) Isolation and purification of fused IGF-I (Type I): Wet cell paste (60 g) was suspended in 150 ml of 10 mM PBS-EDTA (pH 8.0) and cells were lysed by sonication. The cells debris was pelleted by centrifugation at 18,000 rpm for 30 minutes. The pellet was dissolved in 50 ml of 0.1 M Tris-HCl (pH 8.0)/8 M urea and 0.1 M dithiothreitol and centrifuged at 35,000 rpm for 30 minutes at 25°C. The supernatant was collected and applied to a Sephacryl S300 superfine column (5.0 x 86.6 cm; 1700 ml resin) equilibrated with 0.1 M Tris-HCl (pH 8.0)/8 M urea and 10 mM 2-mercaptoethanol. Elution was carried out at 4°C with equilibration buffer, at a flow rate of 0.6 ml/min. Sephacryl S 300 chromatography was conducted and fractions of 17 ml were collected. Sephacryl S300 chromatography was conducted. Assays were performed immediately following fractionation for all chromatography steps. Active fraction were collected and the pooled fraction of 255 ml was dialyzed for 3 hours at room temperature against 8 liters of 1 M acetic acid aqueous solution and then overnight against 8 liters of fresh 1 M acetic acid aqueous solution. The fraction dialyzed was lyophilized to give fused IGF-I (Type I) of 450 mg which contains a desired component. The fused IGF-I (Type I) shows a band at the position of molecular weight 15,500 on 15% SDS PAGE. (2) Elimination of protein peptide LH (Type I) from fused IGF-I (Type I) with cyanogen bromide: The fused IGF-I (Type I) (225 mg) obtained by procedure (1) was dissolved in 36 ml of 60% formic acid. Cyanogen bromide (36 mg) was added and the mixture was allowed to react for 3 hours below 25° C with stirring. After addition of 234 ml of distilled water, formic acid and cyanogen bromide were removed by lyophylization. The residue was dissolved in 36 ml of 1M Tris-HCl (pH 8.0)/8 M urea and 50 mM 2-mercaptoethanol. The resulting solution was dialyzed twice for 3 hours at room temperature against 400 ml of 0.01 M AcONH₄ (pH 4.6)/8 M urea and 50 mM 2-mercaptoethanol (Buffer A) and then overnight against 400 ml of fresh Buffer A. The solution dialyzed was applied to a cationic ion exchange resin CM 52 column (1.6 x 7.5 cm; 15 ml resin) equilibrated with Buffer A. The column was washed with Buffer A (60 ml) at room temperature at a flow rate of 0.25 ml/min and eluted with a linear gradient from Buffer A (120 ml) to 0.2 M AcONH₄/8 M urea and 50 mM 2-mercaptoethanol (120 ml). Fractions (from No. 57 to No. 100) of 2.9 ml were collected. (3) High performance liquid chromatography: The pooled fraction obtained by procedure (2) was applied. column: Beckman Ultrapore RPSC (4.6 x 75 mm) flow rate: 1ml/min elution: linear gadient from 10% to 60 % acetonitrile in 0.01 M trifluoroacetic acid over 50 minutes. The chromatography was repeated 15 times and fractions containing reduced IGF-I were collected and the main peak with a retention time of 29.32 minutes corresponds to reduced IGF-I. Thus reduced IGF-I was obtained about 2.4 mg by the procedures described above. The reduced IGF-I was converted to oxidize IGF-I by usual manner of refolding. The IGF-I was supperimposed with authentic IGF-I gifted by Dr. Humbel on HPLC. (4) Amino acid analysis and sequence analysis of IGF-I: The amino acid composition of IGF-I was obtained using a Walters amino acid analysis system. The amino acid sequence of IGF-I was determined by the combination of Edman's method (DIBITC method) [J. Y. Chang et al : Biochem. J., 153 , 607(1976), Biochim. Biophys. Acta., 578 , 188(1979)] and carboxypeptidase method as shown in Fig. 15.

Claims: A process for the production of IGF-I, which comprises subjecting IGF-I fused to a protection peptide to an elimination reaction in which i) the protective peptide is a protein peptide having methionine as the last amino acid ii) the protective peptide is fused to IGF-I through said methionine, and iii) the elimination reaction is conducted with cyanogen bromide. IGF-I fused to a protective peptide, wherein the protective peptide is a protein peptide having methionine as the last amino acid and is fused to IGF-I through said methionine. IGF-I fused to a protective peptide according to claim 2, wherein IGF-I is fused to protein peptide LH (Type I) having the following amino acid sequence: A gene coding for IGF-I fused to a protective peptide of Claim 2. An expression vector containing a promotor and a gene coding for IGF-I fused to a protective peptide of Claim 4. A transformant containing an expression vector as defined in Claim 5. A process for the production of IGF-I fused to a protective peptide which comprises culturing a transformant as defined in Claim 6.

Inventors: KITAGUCHI, TADASHI, NIWA, MINEO, ONO, HIROKI, SAITO, YOSHIMASA, SATO, SUSUMU, UEDA, IKUO
Applicants: FUJISAWA PHARMACEUTICAL CO., LTD.
Application year: 1985
Main classification: C12N15
IPC codes: C12N15, C12R1, C07K14, C07K1, C12N1, C12P21, C07K19